AGENUS INC AGEN
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances)
Chart by TradingView
2/9
Piotroski F — financial health
-38.04
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $114.2M | — | — | -$77.2M | -$271.1M |
| 2024 | $103.5M | — | — | -$158.9M | -$306.4M |
| 2023 | $156.3M | — | — | -$234.2M | -$148.4M |
| 2022 | $98.0M | — | — | -$228.4M | -$54.9M |
| 2021 | $295.7M | — | — | -$23.7M | $47.9M |
| 2020 | $88.2M | — | — | -$142.6M | -$211.5M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| ARMEN GARO H | See Remarks | 2026-06-12 | Grant | 4,925 | $3.30 |
| ARMEN GARO H | See Remarks | 2026-05-29 | Grant | 4,644 | $3.50 |
| ARMEN GARO H | See Remarks | 2026-05-15 | Grant | 4,540 | $3.58 |
| ARMEN GARO H | See Remarks | 2026-05-01 | Grant | 4,233 | $3.84 |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -38.04 (distress)
- Working capital / assets -0.838
- Retained earnings / assets -9.624
- EBIT / assets -0.089
- Equity / liabilities -0.544
Source: SEC EDGAR filings · CIK 0001098972 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.